In the past two decades, the terminology of MDA5+ DM had been gradually transformed from clinically amyopathic dermatomyositis (CADM) and subsequently is defined by a centerpiece of serologic anti-MDA5 antibodies (1, 2). This evidence concerns the gene IFIH1 and dermatomyositis.